Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564198 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
A Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT02564198: Completed Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor, sponsored by Eli Lilly and Company.
NCT02564198 is a Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants, below the 1,130-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02564198, a Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Primary Outcome
A DLT is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: 1\. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \>7 days 4. Grade ≥3 thrombocytop
Conditions Studied
Interventions
- DRUG Ramucirumab
Study Locations (20)
California
- Children's Oncology Group - Monrovia
- Childrens Hospital of Orange County - Orange
- University of California, San Francisco - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Childrens Hospital of Pittsburgh - Pittsburgh
Alabama
- Childrens Hospital of Alabama - Birmingham
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta at Scottish Rite - Atlanta
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Maryland
- Mark O Harfield-Warren Grant Magnuson Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 1 |
What the finished NCT02564198 record still lists
NCT02564198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 1,130-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Pediatric Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Ramucirumab is the first listed.
NCT02564198 names 20 study sites across 17 states, led by California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT02564198 about?
NCT02564198 is a clinical study titled "A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors". The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
What is the current status of trial NCT02564198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-12-11. Estimated completion is 2019-07-16.
What conditions does trial NCT02564198 study?
This clinical trial studies the following conditions: Pediatric Solid Tumor, Recurrent Tumor, Refractory Tumor, CNS Malignancies.
What interventions are being tested in trial NCT02564198?
The interventions under investigation include: Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02564198?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02564198 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02564198's enrollment target sits among peer trials
29 10th of 10 higher than 1 of 10 other Pediatric Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI